Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

36.72USD
27 Jul 2016
Change (% chg)

$-0.10 (-0.29%)
Prev Close
$36.83
Open
$36.75
Day's High
$36.82
Day's Low
$36.65
Volume
4,209,876
Avg. Vol
33,961,830
52-wk High
$37.19
52-wk Low
$28.25

Latest Key Developments (Source: Significant Developments)

Bind Therapeutics determines Pfizer's $40 mln bid highest
Tuesday, 26 Jul 2016 05:27pm EDT 

Bind Therapeutics Inc : Plans to disclose additional terms of its agreement with Pfizer upon court approval. . Bind Therapeutics determines Pfizer's $40 million bid is highest and best in 363 auction for substantially all of bind's assets .Nanocarrier Co Ltd has been selected as back-up bidder.  Full Article

Bind Therapeutics says two bidders join Pfizer's stalking horse bid
Monday, 25 Jul 2016 07:00am EDT 

Bind Therapeutics Inc : Bids are in addition to pfizer inc.'s initial stalking horse bid of approximately $20 million under section 363 of u.s. Bankruptcy code . Bind therapeutics announces two bidders join pfizer's stalking horse bid in auction for bind's assets . u.s. Bankruptcy court has authorized bind to proceed with an auction on july 25, 2016 .Winning bid is subject to u.s. Bankruptcy court approval and a hearing is scheduled to take place on july 27, 2016.  Full Article

Pfizer gets WHO prequalification for multi-dose vial presentation of Prevenar 13
Tuesday, 19 Jul 2016 08:00am EDT 

Pfizer Inc : Pfizer receives world health organization prequalification for multi-dose vial presentation of Prevenar 13 . Prequalified MDV presentation is expected to be introduced under AMC program in early 2017, for shipment to countries supported by GAVI . Once MDV presentation is introduced under AMC, pricing of $3.10/dose for Prevenar 13 expected to be available to all GAVI-eligible countries .In addition, expanded availability will enable GAVI-Graduated countries to access same pricing until 2025.  Full Article

ARIA study shows superior efficacy of Triumeq for treatment-naïve women with HIV
Monday, 18 Jul 2016 06:16am EDT 

Viiv Healthcare: ARIA study shows superior efficacy of Triumeq for treatment-naïve women living with HIV .Both non-inferiority and superiority endpoints were met.  Full Article

Pfizer announces positive top-line results from phase 3 S-TRAC trial
Friday, 8 Jul 2016 08:00am EDT 

Pfizer Inc : Pfizer announces positive top-line results from phase 3 S-TRAC trial of sutent (sunitinib) as adjuvant therapy in patients at high risk of recurrent renal cell carcinoma . "S-TRAC is first RCC trial of a tyrosine kinase inhibitor to prolong disease-free survival in adjuvant setting" . Adverse events observed for sutent in S-TRAC trial were consistent with its known safety profile . Full efficacy and safety data will be submitted for presentation at esmo 2016 congress in Copenhagen, 07-11 October 2016 .Met primary goal of improving disease-free survival as determined by blinded independent central review in patients with renal cell carcinoma.  Full Article

BRIEF-Pfizer and Germany's Merck KGaA initiate phase III trial
Thursday, 7 Jul 2016 11:56am EDT 

Pfizer Inc : Merck KGaA and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer . New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women .First phase III trial evaluating addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer.  Full Article

Pfizer and Merck initiate phase III trial
Wednesday, 6 Jul 2016 08:00am EDT 

Pfizer Inc : Merck and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer . New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women .First phase III trial evaluating addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer.  Full Article

Bind Therapeutics files motion for sale of assets after accepting stalking horse bid from Pfizer
Friday, 1 Jul 2016 05:30pm EDT 

Bind Therapeutics Inc : Bind Therapeutics files motion for sale of assets after accepting stalking horse bid from Pfizer Inc . Pfizer has also agreed to assume certain contractual liabilities of Bind . Pfizer has agreed to acquire substantially all of Bind's assets for approximately $20 million in cash .Has requested U.S. Bankruptcy court to authorize co to proceed with auction on July 25, 2016 for majority of its assets.  Full Article

Pfizer completes acquisition of Anacor
Friday, 24 Jun 2016 09:00am EDT 

Pfizer Inc : Pfizer completes acquisition of Anacor .Continues to expect transaction to be slightly dilutive to adjusted diluted earnings per share in 2017.  Full Article

Pfizer declares Q3 2016 $0.30 dividend
Thursday, 23 Jun 2016 04:00pm EDT 

Pfizer Inc :Pfizer declares 30-cent third-quarter 2016 dividend.  Full Article

Photo

Bayer drugs secure earnings beat, offset weak crop chems

FRANKFURT Bayer , the German drugmaker trying to acquire U.S. seed company Monsanto , surpassed second-quarter earnings expectations and raised its guidance for the year as strong gains in stroke prevention pill Xarelto offset sluggish farming pesticides markets.